Inbiose NV researches, develops, and produces specialty carbohydrates and related products. It develops fermentation based technology platform suitable for the industrial manufacturing of specialty carbohydrate, called glycans, and produces human milk oligosaccharides (HMO, fucosylated, and sialylated oligosaccharides), infant nutrition, probiotics nutraceuticals, and cosmetic products that helps immune defenses, brain development, gastro-intestinal disorder, anti-microbial and viruses defence mechanisms. The company produces specialty carbohydrates and sugars, such as L-fucose, L-ribose, and sialic acid or human milk oligosaccharides such as fucosyllactose, and sialyllactose; human milk bioactives also called Human Milk Oligosaccharides (HMO), for infant food formula (milk bioactives), fortified and functional food/beverages, health ingredients for human and animal, and over the counter food supplements; and prebiotics and probiotics. It also offers biological system feasibility studies (strain construction and proof of concept); development of upstream fermentation protocols and scale-up for specialty carbohydrate targets through access to pilot plant facilities; fermentation optimization (strain platform screening); downstream process design and development; and research contracts and manufacturing contracts. The company serves human and animal nutraceuticals, biomedical, and agro industries. It has partnership with private or public institutions, KOLs in scientific and life science communities, industrial/medical food manufacturers, pharmaceutical companies, and animal or plant health companies in form of licensing-out, licensing-in, co-development, contract manufacturing, and third party services. The company was founded in 2013 and is based in Ghent, Belgium.